Siemens' PETNET Solutions, a wholly owned subsidiary of Siemens Healthcare, announced it will provide clinical researchers in the greater New York City area with access to gallium-68-labeled prostate-specific membrane antigen (Ga-68 labeled PSMA). This investigational tracer is being studied for prostate cancer imaging using positron emission tomography/computed tomography (PET/CT) in clinical trials throughout the world.

Texas Children's Hospital successfully separated Knatalye Hope and Adeline Faith Mata in late February, completing one of the most complex conjoined twins separations ever. The procedure took months of planning, and Toshiba's Aquilion ONE CT system played a crucial role in determining the feasibility of separating the twins and producing images that helped radiologists build detailed 3-D models of the organs.

Ten weeks of intensive reading intervention for children with autism spectrum disorder was enough to strengthen the activity of loosely connected areas of their brains that work together to comprehend reading, University of Alabama at Birmingham researchers have found. At the same time, the reading comprehension of those 13 children, whose average age was 10.9 years, also improved.

Brainlab announced first patient treatments in March on a fully integrated radiation oncology solution that combines its ExacTrac patient positioning with the Elekta Versa HD linear accelerator (LINAC). Working in synergy, these technologies determine positioning and treatment accuracy for cancer patients.

Concussion, also known as mild traumatic brain injury (MTBI), is a common medical problem affecting cognitive function and quality of life in some individuals.

IBA (Ion Beam Applications S.A.) and Royal Philips announced the signing of an exclusive agreement to enhance access to proton therapy in India. The alliance combines IBA’s strengths in proton therapy and Philips’ expertise in clinical informatics and innovative imaging techniques for therapy planning and guidance.

Augmenix Inc. announced the publication of the 222-patient pivotal study designed to evaluate safety and efficacy of the SpaceOAR System in men undergoing prostate radiotherapy. By creating space between the prostate and rectum, the SpaceOAR System is intended to reduce the radiation dose delivered to the rectum during prostate radiotherapy. The favorable results from the multi-center, randomized, single-blind study led to the April 1, 2015, U.S. Food and Drug Administration (FDA) clearance of the SpaceOAR System.